OXERVATE

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, Poland, United States

Active ingredients

The drug OXERVATE contains one active pharmaceutical ingredient (API):

1 Cenegermin UNII B6E7K36KT8 - CENEGERMIN

Cenegermin, a recombinant form of human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e. TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors. The treatment with cenegermin, administered as eye drops, is intended to allow restoration of corneal integrity. Read about Cenegermin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OXERVATE Eye drops, solution	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01XA24		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1749764
Country: FR	Base de données publique des médicaments	Identifier(s): 60963595
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8523
Country: IT	Agenzia del Farmaco	Identifier(s): 045383015
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1083402
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100392037
Country: US	FDA, National Drug Code	Identifier(s): 71981-020